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Ignoring endotoxin
In 1947, Paul Beeson showed that rabbits repeatedly injected with certain 
bacteria eventually become resistant to the bacteria’s fever-provoking 
effects—a phenomenon known as endotoxin tolerance.
When bacteria invade, the immune 
system reacts violently to bacterial 
endotoxin (or lipopolysaccharide [LPS])—
a component of gram-negative bacterial 
cell walls. Why then does the immune 
system slowly stop reacting to LPS after 
repeated exposure? Perhaps this process 
allows the body to prevent excessive 
inflammation; with enough under-
standing, doctors may be able to ma-
nipulate the process too.
Endotoxin tolerance was first de-
scribed in the early 1900s when fever 
therapy—the intravenous injection of 
  fever-inducing bacteria LPS—was used in 
an attempt to shrink tumors and to treat 
certain infectious diseases (for review see 
reference 1). But patients often developed 
tolerance to the fever-inducing agent, 
requiring progressively higher doses to 
generate elevations in body temperature.
REsting blame
In the early 1940s, Beeson—then an 
assistant professor at Emory University— 
reproduced LPS tolerance in rabbits by 
injecting them daily with vaccine strains 
of bacteria. As in humans, the injections 
caused progressively milder and more 
transient fevers (2). Injecting endotoxin 
frequently was critical, as rabbits injected 
only once or twice per week developed 
only a low level of tolerance. The toler-
izing effect was also nonspecific: tolerized 
rabbits remained fever free when exposed 
to either the original tolerizing strain or 
an unrelated strain of bacteria.
In search of a mechanistic explana-
tion, Beeson attempted to transfer the 
effect using serum from tolerized rab-
bits. Rabbits that received the serum 
remained responsive to LPS, making it 
clear that antibodies to LPS were not 
sufficient. Also dispensable was the fe-
ver itself, as treating the rabbits with 
fever-reducing drugs did not block tol-
erance induction. The blame instead 
fell on cells of the reticuloendothelial 
(RE) system—now known to include 
macrophages and endothelial cells—as 
plugging up the RE system in tolerant 
animals (using a radiological contrasting 
agent called thorotrast) restored their 
responsiveness to LPS (3).
Beeson later showed that tolerance 
was associated with an accelerated clear-
ance of LPS from the circulation. He 
hypothesized that repeated injections 
with fever-causing (pyrogenic) bacteria 
somehow enhanced the phagocytic ca-
pacity of RE cells, which rapidly cleared 
the bacterial toxin from the body, thus 
protecting other cells and tissues from its 
fever-inducing effects. Beeson published 
these observations in 1947 in The Journal 
of Experimental Medicine (2, 3).
Off the mark
Although later studies confirmed that 
endotoxin was cleared more rapidly from 
tolerant animals, Beeson’s RE cell model 
did not hold up for long. “Beeson didn’t 
do the right control experiment,” says 
Sheldon Greisman, who studied endo-
toxin at the University of Maryland, “He 
didn’t give thorotrast to nontolerant 
  animals.” When Greisman and his col-
leagues repeated the experiment, they 
found that the increased fever caused 
by blocking the RE system was seen in 
both tolerant and nontolerant animals—
  although the response was still milder 
in the tolerant animals (4).
Blocking the RE system, says 
  Greisman, “was not simply diverting 
[more] endotoxin to other tissues.” 
In fact, endotoxin primarily affected 
the liver, where the majority of RE 
cells reside. Later studies by Charles 
  Dinarello (not using thorotrast) showed 
that liver   macrophages from nontoler-
ant rabbits produced a soluble pyrogen 
when stimulated with LPS; those from 
tolerant animals did not—a finding 
  Greisman later confirmed in vivo (5, 6).
Multifaceted mechanism
We now know that myriad mechanisms 
are involved in tolerance induction, 
including down-regulation of the LPS 
receptor Toll-like receptor (TLR)-4, 
decreased production of inflammatory 
cytokines, and alterations in TLR4-
induced signaling pathways (for review 
see reference 7). Yet despite decades of 
research, the physiological role of endo-
toxin tolerance remains mysterious, per-
haps in part because of an inability to 
inhibit tolerance induction without also 
eliminating initial LPS responsiveness.
But the evolutionary conservation 
of endotoxin tolerance suggests that it 
is a good thing. “If you’ve been bitten 
by a saber-toothed tiger,” says sepsis 
specialist Mitchell Fink (University of 
Pittsburgh), “that is a big inflammatory 
stimulus, and you don’t want to be 
consumed by systemic inflammation.” 
But tolerance also has a down side: it 
occurs in critically ill patients, render-
ing them more susceptible to secondary 
infections. “If we can figure out how to 
manipulate this [phenomenon],” says 
Fink, “we’ll have a way to manipulate 
the inflammatory response at will.”
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